ArticleMaterials today. Bio2025
A reagent-free, fouling-resistant electrochemical multifunctional peptide sensor for highly sensitive and rapid detection of Alzheimer's disease biomarkers.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
β-amyloid (Aβ) aggregates are critical biomarkers for the early diagnosis of Alzheimer's disease (AD). Numerous studies have shown that blood-based detection of Aβ aggregates can achieve similar or higher diagnostic accuracy than clinical cerebrospinal fluid tests. In this study, a reagent-free, anti-fouling electrochemical sensor based on a peptide aptamer was developed. This sensor exhibited anti-fouling and specific recognition capabilities, enabling highly sensitive and selective quantitative detection of Aβ aggregates in blood. The multifunctional peptide (MF-peptide) incorporated a hydrophilic sequence of alternating lysine (K) and glutamic acid (E) residues into the Aβ recognition peptide. The MF-peptide sensor was fabricated via the self-assembly of the MF-peptide onto a working electrode modified with gold nanoparticles. Experimental results revealed that the sensor exhibited excellent sensitivity to Aβ aggregates, with a strong bilinear response over a range of 0.3 fM-0.5 pM and a detection limit of 0.1 fM. The entire detection process was completed within 25 min. Moreover, the sensor displayed strong resistance to high concentrations of endogenous interferents (interference coefficient <12.76 %) and excellent selectivity in the presence of both interferents and Aβ aggregates. Additionally, the sensor was successfully used to accurately detect Aβ aggregates in human serum, maintaining its excellent bilinear response. This study presents a novel, efficient, and rapid strategy for detecting Aβ aggregates in human serum without complex pre-processing and provides practical support for the early clinical diagnosis of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.